<SEC-DOCUMENT>0001615774-17-001132.txt : 20170320
<SEC-HEADER>0001615774-17-001132.hdr.sgml : 20170320
<ACCEPTANCE-DATETIME>20170320073727
ACCESSION NUMBER:		0001615774-17-001132
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170320
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170320
DATE AS OF CHANGE:		20170320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		17700075

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s105613_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report (Date of earliest event
reported): March 20, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEKTAR THERAPEUTICS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact Name of Registrant as Specified
in Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><B>0-24006</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center"><B>94-3134940</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or Other Jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Incorporation)</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>(Commission File Number)</B></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>455 Mission Bay Boulevard South</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Francisco, California 94158</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of Principal Executive Offices
and Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (415) 482-5300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 95%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 95%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 95%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 95%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On March 20, 2017, Nektar Therapeutics,
a Delaware corporation (&ldquo;Nektar&rdquo;), issued a press release (the &ldquo;Press Release&rdquo;) announcing the results
from the SUMMIT-07 Phase 3 efficacy study for NKTR-181 in the treatment of patients with moderate to severe chronic low back pain.
A copy of the Press Release reporting results from the Phase 3 Study is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In the Press Release, Nektar announced that
it would hold a Webcast conference call on March 20, 2017 at 5:45 a.m. (Pacific Time)/8:45 a.m. (Eastern Time) on March 20, 2017
to review the results from the Phase 3 SUMMIT-07 study. This conference call is accessible through a link that is posted on the
home page and Investor section of the Nektar website: http://www.nektar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in
this report, including the exhibit hereto, is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not
be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><B>Item&nbsp;9.01</B></TD><TD STYLE="width: 25pt"></TD><TD STYLE="text-align: justify"><B>Financial Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><B>Exhibit</B><BR>
<B>Number</B>&nbsp;</TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 88%"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Press Release titled &ldquo;NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain&rdquo; issued by Nektar Therapeutics on March 20, 2017. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 44%"><B>NEKTAR THERAPEUTICS</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>March 20, 2017</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><I>/s/ Mark A. Wilson</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Mark A. Wilson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>General Counsel and Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: center"><B>Exhibit</B><BR>
<B>No.</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; text-align: left; vertical-align: bottom; border-bottom: Black 1pt solid"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release titled &ldquo;NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain&rdquo; issued by Nektar Therapeutics on March 20, 2017.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s105613_ex99-1.htm
<DESCRIPTION>EXHIBIT 99-1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="logo_ex99-1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>NKTR-181
Meets Primary and Secondary Endpoints in Phase 3 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>SUMMIT-07
Study in Chronic Pain</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>NKTR-181
Significantly Reduced Pain in Patients with Moderate to Severe </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>Chronic
Low Back Pain </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>Primary
Efficacy Endpoint Achieved (p=0.0019)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>Analyst
Conference Call and Webcast </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>Today
at 5:45 a.m. PDT/8:45 a.m. EDT</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>San Francisco, March
20, 2017</B> &ndash; Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from the SUMMIT-07 Phase 3 efficacy study
of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist
molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard
opioids.<SUP>1</SUP>&nbsp; </FONT>The U.S. Food and Drug Administration (FDA) has granted the investigational medicine NKTR-181
Fast Track designation for the treatment of moderate to severe chronic pain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&ldquo;The data from this
efficacy study are extremely important because they demonstrate that NKTR-181 produces strong analgesia in patients suffering from
chronic pain while NKTR-181 has also demonstrated significantly lower abuse potential than oxycodone in a human abuse potential
study,&quot; said&nbsp;clinical investigator Martin Hale, M.D., medical director of Gold Coast Research. &quot;</FONT>While standard
opioid analgesics, including abuse-deterrent formulations, have been the most effective way to treat chronic pain, they are associated
with serious safety concerns and many opioid-na&iuml;ve patients fear taking them because of the potential for abuse and addiction.
<FONT STYLE="background-color: white">The data for NKTR-181 suggest that it is a transformational pain medicine that could fundamentally
change how we treat&nbsp;patients with chronic pain conditions.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The SUMMIT-07 study compared
twice-daily dosing of NKTR-181 tablets to placebo in the treatment of over 600 </FONT>patients with moderate to severe chronic
low back pain who were new to opioid therapy (opioid-na&iuml;ve). <FONT STYLE="background-color: white">The clinical trial met
the primary efficacy endpoint of the study in demonstrating significantly improved chronic back pain relief with NKTR-181 compared
to placebo (p=0.0019). Key secondary endpoints of the study were also met with high statistical significance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Pain is one of the most
common reasons people seek medical treatment.<SUP>2</SUP> </FONT>Low back pain is the second most common cause of disability for
adults in the U.S.<FONT STYLE="background-color: white"><SUP> 3</SUP></FONT> Approximately 149 million work days are lost every
year because of low back pain, with total costs estimated to be $100 to 200 billion a year (of which two-thirds is due to lost
wages and lower productivity).<FONT STYLE="background-color: white"><SUP> 4</SUP> A study published in the American Pain Society's
<I>The Journal of Pain</I> in October 2014 estimated that 19 percent of the U.S. population, or 39 million people, suffer from
some type of persistent pain.<SUP>5</SUP> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Phase 3 SUMMIT-07 study used an
enriched-enrollment randomized withdrawal (EERW) trial design in patients with moderate to severe chronic low back pain. The trial
included an open-label titration period in which patients were titrated to a tolerated, effective dose of NKTR-181 (100 mg to 400
mg twice-daily). Following this open-label titration period, patients entered a double-blind, placebo-controlled treatment period
in which they were randomized 1:1 to either continue to receive the tolerated, effective dose of NKTR-181 or to receive matching
placebo (i.e. active drug was withdrawn) for a period of 12 weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">During the open-label titration period
of the trial in which patients were titrated to a tolerated, effective dose of NKTR-181, average pain scores dropped by 65% (from
6.73 at screening to 2.32 at randomization, n=610).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The primary endpoint of the study was
mean change in the weekly average pain score in the double-blind randomized treatment period from baseline (end of open-label titration
period) to week 12 (end of double-blind randomized treatment period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Primary and key sensitivity analyses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">During the double-blind randomized treatment period of the trial,
average pain scores increased more in the placebo arm versus NKTR-181 at week 12 from randomization baseline (1.46, placebo versus
0.92, NKTR-181, p=0.0019, n=610).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">83% of patients completed the 12-week double-blind randomized treatment
period and for these study completers, average pain scores increased more in the placebo arm versus NKTR-181 at week 12 from baseline
(1.25, placebo versus 0.56, NKTR-181, p&lt;0.0001, n=504).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Key secondary endpoints:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A statistically significant proportion of patients on NKTR-181 experienced
pain reductions greater than 30% compared to placebo (71.2% versus 57.1%; p=0.0003). </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A statistically significant proportion of patients on NKTR-181 experienced
pain reductions greater than 50% compared to placebo (51.1% versus 37.9%; p=0.001).</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A statistically significant proportion of patients on NKTR-181 reported
their general overall status and quality of life as &ldquo;improved&rdquo; or &ldquo;very much improved&rdquo; compared to placebo
as assessed by the Patient&rsquo;s Global Impression of Change (PGIC) of pain medication questionnaire (51.5% versus 33.2%; p&lt;0.0001).
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
study also demonstrated that NKTR-181 had a favorable safety profile and was well tolerated. During the double-blind randomized
treatment period, the most commonly reported adverse events for patients (&gt;5%) were nausea (10.4%) and constipation (8.7%) in
the NKTR-181 arm as compared to nausea (6.0%) and constipation (3.0%) in the placebo arm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Patients randomized to NKTR-181 as
compared to placebo reported more favorable sleep outcomes as measured by the validated Medical Outcomes Study (MOS) Sleep Scale,
which captures debilitating aspects of sleep most strongly associated with chronic pain. <FONT STYLE="background-color: white">Patients
</FONT>reported better overall quality of sleep with less sleep problems on NKTR-181 versus placebo. There were no differences
in daytime sleepiness on NKTR-181 versus placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><BR>
Full data from the SUMMIT-07 study will be presented at a medical meeting in the second half of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;As a new molecule, NKTR-181 has a highly differentiated
profile with the potential to be one of the most important advancements in pain medicine,&rdquo; said Howard W. Robin, President
and CEO of Nektar Therapeutics. &ldquo;Given the seriousness of the current opioid epidemic in the U.S. and the significant number
of people battling chronic pain, we are committed to bringing this new molecule to patients and physicians as quickly as possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2017, results from a separate human abuse potential
trial of NKTR-181 were published in the American Academy of Pain Medicine&rsquo;s journal of <B><I><U>Pain Medicine</U></I></B>.
The human abuse potential study assessed the relative abuse potential of a range of therapeutic doses of NKTR-181 (100 mg to 400
mg), the same dose range evaluated in the Phase 3 SUMMIT-07 efficacy trial. <FONT STYLE="background-color: white">All doses of
NKTR-181&nbsp;tested for abuse potential were rated similarly to placebo in &quot;drug liking&quot; and &quot;feeling high&quot;
scores and had highly statistically significant lower &quot;drug liking&quot; scores and reduced &quot;feeling high&quot; scores
as compared to 40 mg oxycodone (p &lt; 0.0001).&nbsp;&nbsp;In addition, all doses of NKTR-181 also scored lower on sleepiness
when compared to 40 mg oxycodone (p &lt; 0.0001).&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&quot;It is clear that
there is a pressing societal need for better and safer analgesics,&quot; said Dr. Jack Henningfield, Ph.D., </FONT><FONT STYLE="background-color: #FEFEFE">Adjunct
Professor of Behavioral Biology in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School
of Medicine and Head of Health Policy and Abuse Liability at </FONT><FONT STYLE="background-color: white">Pinney &amp; Associates
in Bethesda, MD. &quot;In the human abuse potential study, even the highest analgesic dose of NKTR-181 was barely distinguishable
from placebo with respect to both drug-liking and feeling high and these effects were modest compared to those produced by oxycodone.&nbsp;
Drug-liking and feeling high are two of the most important metrics that help us understand the abuse potential of a medicine.&nbsp;
Importantly, as NKTR-181 is a new chemical entity, the properties of NKTR-181 are inherent to its molecular structure and independent
of any abuse-deterrent formulation.&nbsp; Today&rsquo;s reported efficacy and safety results, along with the human abuse potential
data published this past week in Pain Medicine, suggest NKTR-181 may be a major advance towards safer opioid therapy for the treatment
of moderate to severe chronic pain.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conference Call and Webcast Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nektar will host a conference call and webcast presentation
today, March 20, 2017, at 8:45 a.m. Eastern Daylight Time to discuss the study results. The call can be accessed by dialing (877)
881-2183 (U.S.) or (970) 315-0453 (international), and entering passcode 89288091. To access the live webcast, or the subsequent
archived recording, visit the Investors section of the Nektar website at <U>www.nektar.com</U>. The webcast will be available
for replay on Nektar's website for two weeks following the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About NKTR-181</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">NKTR-181 is the first
long-acting, selective mu-opioid agonist designed to provide potent pain relief without the inherent high levels of euphoria which
lead to abuse and addiction with standard opioids. </FONT>The novel molecular structure of NKTR-181 is designed to have low permeability
across the blood-brain barrier in order to slow its rate of entry into the brain and attenuate the dopamine release that underlies
euphoria. <FONT STYLE="background-color: white">NKTR-181 is the first opioid molecule to exhibit reduction in specific CNS-mediated
side effects, like euphoria, through the strategic alteration of brain-entry kinetics.<SUP> </SUP> NKTR-181 is an investigational
medicine and has not been approved by the FDA or any other regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Current strategies of
abuse deterrence to address the addictive qualities of standard opioids rely on formulations alone. All abuse-deterrent formulations
are limited in that once the opioid within the formulation is liberated through tampering, it can rapidly enter the brain and is
highly euphorigenic. Preclinical data show that the inherent properties of NKTR-181 reduce its rate of entry into the brain compared
to standard mu opioids, regardless of route of administration.<SUP>12</SUP> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the SUMMIT-07 Study Design </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SUMMIT-07 used an enriched-enrollment, randomized withdrawal
(EERW) design and enrolled opioid-na&iuml;ve patients ages 18 to 75 years who had moderate to severe non-neuropathic chronic low
back pain for at least six months. The study included an open-label, dose-titration period followed by a randomized, double-blind,
placebo-controlled 12-week treatment period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the open-label titration phase, study participants with
pain scores of between 5 and 9 were titrated on NKTR-181 tablets administered orally twice daily until they experienced an adequate
and sustained pain response (a drop of at least 2 points and a pain score below 4 on the numeric rating scale (NRS) of 0-10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patients who achieved this were then randomized on a 1:1 basis
to either continue receiving their analgesic dose of NKTR-181 or to receive placebo (i.e. the active drug was withdrawn) during
the double-blind 12-week treatment period. A total of 610 patients were randomized into the double-blind treatment period. The
primary outcome was based on assessing worsening of pain in the placebo arm relative to the active arm for patients who achieved
substantial analgesic responses with NKTR-181. The primary efficacy endpoint was a change in pain as measured by the change in
a patient's weekly pain score from baseline to week 12 of the<FONT STYLE="background-color: white"> randomized, double-blind, treatment
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Opioids and Abuse</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pain is one of the most common reasons people seek medical treatment.<FONT STYLE="background-color: white"><SUP>2
</SUP></FONT>A study published in the American Pain Society's <I>The Journal of Pain</I> in October 2014 estimated that 19 percent
of the U.S. population, or 39 million people, suffer from persistent pain.<FONT STYLE="background-color: white"><SUP>5</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Opioids are considered the most effective therapeutic option
for pain. In 2016, 230 million opioid prescriptions were written in the U.S.<FONT STYLE="background-color: white"><SUP>6 </SUP></FONT>However,
these painkillers can cause serious side effects such as respiratory depression and sedation, and they have the potential for addiction,
abuse and misuse.<FONT STYLE="background-color: white"><SUP>7 </SUP></FONT>In 2014, nearly 2 million Americans either abused or
were dependent on prescription opioid pain relievers.<FONT STYLE="background-color: white"><SUP>8 </SUP></FONT>One in five Americans
say they have a family member who has been addicted to prescription painkillers.<FONT STYLE="background-color: white"><SUP>9 </SUP></FONT>In
2015, there were nearly 22,000 deaths involving prescription opioids in the U.S.<FONT STYLE="background-color: white"><SUP>10</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">According to a 2011 Institute of Medicine Report, pain is a
significant public health problem that costs society at least $560 to 635 billion annually.<FONT STYLE="background-color: white"><SUP>
2</SUP></FONT> In the U.S., prescription opioid abuse costs were about $78.5 billion in 2013.<FONT STYLE="background-color: white"><SUP>11</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Nektar Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nektar Therapeutics is a research-based biopharmaceutical company
whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&amp;D pipeline
of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary
and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco,
California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and
its drug development programs and capabilities may be found online at <U>http://www.nektar.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cautionary Note Regarding Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I>This press release
contains forward-looking statements which can be identified by words such as: &quot;plan,&quot; &quot;expect,&quot; &quot;may,&quot;
&quot;will&quot; and similar references to future periods. Examples of forward-looking statements include, among others, statements
we make regarding </I></FONT><I>the potential therapeutic benefit of NKTR-181 for treating patients with pain, the potential importance
of NKTR-181's development in the area of new pain medicines, the risks of opioid abuse resulting from new and existing pain medicines,
future development plans for NKTR-181 (including, but not limited to, future clinical development plans and future regulatory filings
seeking regulatory approval for NKTR-181), the potential timeframe for commercial availability of NKTR-181, and certain other statements
regarding the prospects and potential of NKTR-181 specifically, and Nektar's business and technology platform generally. <FONT STYLE="background-color: white">Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends,
the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our
actual results may differ materially from those indicated in the forward-looking statements. </FONT>Therefore, you should not rely
on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those
indicated in the forward-looking statements include, among others: (i) challenges and uncertainties inherent in pharmaceutical
research and development, including the uncertainty of future clinical and regulatory success, where the risk of failure remains
high and failure can unexpectedly occur at any stage prior to regulatory approval due to lack of sufficient efficacy, safety considerations
or other factors; (ii) the regulatory pathway to review and approve NKTR-181 for use in patients, even with a Fast Track designation
by the FDA, is subject to substantial uncertainty; (iii) regulations concerning and controlling the access to opioid-based pharmaceuticals
are strict and there is no guarantee which scheduling category will apply to NKTR-181 if regulatory approval is achieved; (iv)
the partnering process for NKTR-181 is at a very early stage and there is therefore substantial uncertainty as to the timing and
terms of a potential partnership, or the success of our partnering efforts; (v) drug manufacturing challenges which can delay or
render unavailable sufficient supplies of NKTR-181; (vi) changing standards of care and new regulations (including, but not limited
to, standards and regulations related to health care cost containment) can affect the use NKTR-181 and commercial success following
a regulatory approval; (vii) Nektar's patent applications for NKTR-181 may not issue in one or more jurisdictions, patents that
have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future;
(viii) the outcome of any existing or future intellectual property or other litigation related to Nektar's proprietary product
candidates, including, without limitation, NKTR-181, is unpredictable and could have a material adverse effect on our business;
and (ix) certain other important risks and uncertainties set forth in Nektar's Annual Report on Form 10-K for the year ended December
31, 2016 filed with the Securities and Exchange Commission on March 1, 2017. Any forward-looking statement made by us in this press
release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as
a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jennifer Ruddock of Nektar Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">415-482-5585</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jodi Sievers of Nektar Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">415-482-5593</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Media:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dan Budwick of Pure Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">973-271-6085</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>dan@purecommunications.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><FONT STYLE="background-color: white">Hyman, Steven E., Harvard Review of Psychiatry. 2(1):43-46, May/June 1994. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD><FONT STYLE="background-color: white">2011 National Academy of Sciences. Relieving Pain in America: A Blueprint for Transforming
Prevention, Care, Education and Research, 2010 Decision Resources, and Harstall, C. How prevalent is chronic pain? Pain Clinical
Updates X, 1-4 (2003). </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Arch Intern Med 2009 February 9; 169(3): 251-258.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>World Health Organization: Priority Medicines for Europe and the World Update Report, 2013; Background Paper 6.24, Low Back
Pain.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD><FONT STYLE="background-color: white"><U>http://americanpainsociety.org/about-us/press-room/persistent-pain-incidence-news-release</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD><FONT STYLE="background-color: white">IMS, 2016.23.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD><FONT STYLE="background-color: white">Melnikova, I, Pain Market, Nature Reviews Drug Discovery, Volume 9, 589-90 (August 2010).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD><FONT STYLE="background-color: white">Substance Abuse and Mental Health Services Administration, National Survey on Drug Use
and Health, 2014.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD>The Washington Post/Kaiser Family Foundation Survey of Long-Term
                                         Prescription Painkiller Users and Their Household Members: <U>http://kff.org/other/report/the-washington-post-kaiser-family-foundation-survey-of-long-term-prescription-painkiller-users-and-their-household-members</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD>CDC. Wide-ranging online data for epidemiologic research
                                         (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at
                                         <U>http://wonder.cdc.gov.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">11.</TD><TD>Med Care. 2016 Oct;54(10):901-6.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">12.</TD><TD>2010 Society of Neuroscience Annual Meeting (Nov 13-17, #HHH11).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_ex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_ex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ - #] P$1  (1 0,1 ?_$ .L   (" @,! 0
M      D*!P@  00%!@," 0 " 04! 0             ("0<  P0%!@$"$
M!0(#!00$! P0# <    ! @,$!1$& !('(3$3%0A!(A0)46$R%G&!0A=R(S/3
MU"4UM7:6&!G!T5)BLL*3)*159=4V5W<X\*&Q0S24M%:&MC='D>&B5&1F)Q$
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M#O':()(QFXYA+J@/].LOK[S%?3W A7FN D;)94?.@41YB6$AP&3>@.0]*N'
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MY"MV2T4R11TM>P&D$J&U2ISD>N<=_P!W&[U>J.<';[HLNUCU$\M2NDA E\R
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MQ5,1WO,CF/8-":;57Z@4ARY.)(9 /WQ2Y89A, 8[8.U;GEY=++"%8,I.P#W
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M1KE%:<]&_3=J.;2Z%3M56[*1$:S3DI%^HO<TZW&)"02/(O'3@JD?'%,IW#
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M[0#9\&-0#;2@M]]>WLQCU/>AYTI:S4]S9=="DG(NEIVTJ ()!6V@K&$Y2VG
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M2W%0K39A,/,ZFJJ+F)>6'@.%271Q1EO!"5#+Y=\H;!RZJ1<>7MFX).>IM;:
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-!/.R_A<WN?\ I'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
